Alpha Core Capital LLC Cardiff Oncology, Inc. Transaction History
Alpha Core Capital LLC
- $2.88 Billion
- Q3 2025
A detailed history of Alpha Core Capital LLC transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Alpha Core Capital LLC holds 109,926 shares of CRDF stock, worth $236,340. This represents 0.01% of its overall portfolio holdings.
Number of Shares
109,926
Previous 101,575
8.22%
Holding current value
$236,340
Previous $319,000
30.41%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding CRDF
# of Institutions
126Shares Held
22MCall Options Held
966KPut Options Held
208K-
Vanguard Group Inc Valley Forge, PA3.59MShares$7.72 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.63MShares$5.65 Million0.0% of portfolio
-
Blair William & CO Chicago, IL2.21MShares$4.76 Million0.01% of portfolio
-
Laurion Capital Management LP New York, NY1.8MShares$3.86 Million0.11% of portfolio
-
Geode Capital Management, LLC Boston, MA1.54MShares$3.32 Million0.0% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $93.2M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...